Navigation Links
Halozyme Receives $5.5 Million Payment From Baxter
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced receipt of $5.5 million from Baxter Healthcare Corporation representing the final prepaid product-based payment due under the terms of its HYLENEX licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been booked as deferred revenue.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com.

    Halozyme Contact
    Robert H. Uhl
    Senior Director, Investor Relations
    (858) 704-8264
    ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Erlab , ... personnel since 1968 and Burdinola, supplier of laboratory furniture ... new filtered fume hood. , By integrating ... hood, Burdinola will now offer an innovative solution utilizing ... range of chemicals, best-in-class detection technology, and communication for ...
(Date:9/23/2014)... , Sept. 23, 2014 ... the "Proteomics Markets for Research and IVD ... Technologies)" report to their offering. ... for proteomics applications, both in their research use ... proteins, including the study of the structure and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4ExakTime Makes Inc. 5000 List for the Fifth Time 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , SILVER SPRING, Md. , Feb. ... announced today that it will release its fourth quarter and ... February 16, 2010 . , United Therapeutics will host a ... 9:00 a.m. Eastern Time .  The teleconference is accessible ...
... Ind. , Feb. 9 The American Psychiatric Association ... to prepare and manage all industry-supported symposia (ISS) programming at its ... 22-26, 2010 . , CME Enterprise will manage all elements ... partnership with the APA. , "It is a tremendous honor ...
... , , , , , , LEUVEN, ... - Paper Examines the Potential of Microplasmin to Improve the Treatment,of ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery ... today that the positive,microplasmin Phase II trial results, evaluating the product,s efficacy ...
Cached Biology Technology:CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
(Date:9/23/2014)... The successful rise and fall of an athlete,s moving body ... tendons, putting the many angles and intersecting planes literally ... joint to the test. But it,s more than just a ... devastating of sports injuries: the ACL or anterior cruciate ligament ... sits at the center of the knee joint and ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... award funds to support the next phase of its ... of predicting drug safety and effectiveness. Researchers will collaborate ... chips and combine them into an integrated system that ... Led by the National Center for Advancing Translational Sciences ... million in 2014 with additional support over the remaining ...
Breaking Biology News(10 mins):Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... just a single island in the remote South Pacific, is ... also one of the oldest flowering plants, having branched off ... Indiana University, with the U.S. Department of Energy Joint Genome ... Research for Development in New Caledonia, have determined a remarkable ...
... Ven, Department of Molecular Biology and Genetics and the ... microRNA-128 just published in Science . In the ... amount of microRNA-128 in specific neurons that react to ... in these neurons in neonatal mice, it results in ...
... a cloudless day in Dangriga, a coastal city in southern ... wall of their sun-strewn lab is lined with the usual ... tubes. Swathed in purple gloves, they measure samples, mix gels ... usual class this is not. It is part of ...
Cached Biology News:A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3New research provides insight into epilepsy 2Beyond Mendel 2Beyond Mendel 3Beyond Mendel 4
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... The Dyad Disciple thermal cycler is a ... may also be operated independently, using a ... of interchangeable Alpha units (sample-holder, heat-pump assemblies), ... as the Chromo4 real-time detector. Peltier heat ...
...
I-Ab MHC Class II...
Biology Products: